Mohana Roy, MD
@MohanaRoy1
Followers
402
Following
1K
Statuses
592
@stanfordcancer Clinical Assis Prof.+ Assoc dir. of cancer quality, via @BIDMC_IM, Thoracic Onc + merging QI with health equity, brunch lover, mom of 2 24/7
Palo Alto, CA
Joined July 2018
Excited to report @StanfordCancer distress screening implementation process, out now @ASCO_pubs #JCOOP- a truly multidisciplinary effort @JoelNealMD @kavithapallonc @EbenRosenthal @BlayneyDouglas
0
2
12
RT @NicoGagelmann: Let's learn hematology in 2025🩸 Day 34: thrombocytopenia in liver cirrhosis
0
81
0
RT @StephenVLiu: Report from @ASCO on US oncologist well-being show 59% of oncologists report burnout and 75% of them plan on decreasing cl…
0
52
0
Beautiful, Poignant and Deeply Sad- thank you for sharing your journey and the deep issues with the monetization of healthcare, especially cancer care @SamiraDaswani @manta_cares Please read: Business of Health Care and the Personal Cost of Cancer Care | JCO Oncology Practice
0
0
0
RT @JordiRemon: 2024: Fortunately is difficult to merge all ttx for NSCLC 🫁 in 1 slide. Hwv, still pending: ✏️avoid “me too” approvals if p…
0
121
0
RT @AaronGoodman33: Clinic visits explaining MGUS or other incidental findings take me longer than a new consult for relapsed AML. The a…
0
19
0
RT @TejasPatilMD: In pts with #EGFR #NSCLC, what is the value of continuing osimertinib with platinum-pemetrexed after progression vs stop…
0
71
0
RT @aparna1024: one of few who disagree (a bit). IDEA non inferiority & accept some (albeit tiny) efficacy loss. We 💯 push oxali too much b…
0
3
0
Inspiring Joe Simone quality lecture on perseverance of a journey of finding a problem (uncontrolled symptoms), finding a solution( ePRO) , implementation and more @EthanBasch1 #ASCOQLTY24
0
5
6
RT @KatsuakiMaehara: 🫁 #FLAURA2 & #MARIPOSA 🫁 🌟 It has been a year since FLAURA 2 was presented at #WCLC2023 and MARIPOSA at #ESMO2023, a…
0
11
0
RT @StephenVLiu: Real world study of first-line nivolumab + ipilimumab for pleural #mesothelioma (ImmunoMeso LATAM) @ClinicalLung from @Die…
0
21
0
RT @fred_hirsch: Benefit of Immunotherapy in EGFR+ transformed SCLC ! Interesting data at WCLC #MedIQWCLC24 #WCLC24
0
11
0
RT @KatsuakiMaehara: 🫁 Lung Cancer - ICIs data 🫁 🌟 Summary of 5-year (long follow-up) data 🌟 NSCLC (NSQ & SQ) #Immunotherapy
#Lungcancer…
0
78
0
RT @ogarrieta: Most lung cancer screening programs primarily target subjects with a history of smoking as the leading risk factor. Our rece…
0
45
0
RT @SuyogCancer: Road map for treatment in metastatic CRC. Useful for clinical practice. @ASCO
0
49
0
RT @TheLancet: Lung cancer is a significant public health issue in Asia, representing one of the leading causes of cancer-related mortality…
0
38
0
RT @karima_oualla: Excellent Keynote lecture on the equity , diversity and inclusion in global oncology by @asco ambassador @amitbehl
@Pet…
0
7
0
RT @KE_Gallaway: Impressive results with TIL monotherapy in IO-refractory NSCLC! @DCarboneMD shares multiple add…
0
3
0
RT @YaleHemOnc: Excited to share our fellow @ThejalSrikumar's discussion with @OncData at @ASCO about our program's innovative Professional…
0
3
0
RT @ANCO_News: Join ASCO President-Elect, Eric Small, MD, FASCO from UCSF for a panel discussion at this year's ANCO's ASCO24 Highlights Me…
0
3
0